Literature DB >> 18041935

Overview of Parkinson's disease.

Mark Lew1.   

Abstract

This overview of Parkinson's disease is designed to serve as a background to the discussion elsewhere in this supplement on the pharmacotherapy used in its management. Parkinson's disease is a common progressive neurodegenerative condition associated with significant disability and negative impact on quality of life. Although the cause of Parkinson's disease is unknown, the pathologic manifestation involves the loss or dysfunction of dopaminergic neurons in the substantia nigra pars compacta. Characteristic clinical manifestations include difficulty with coordinated movement such as asymmetric resting tremor, rigidity, and bradykinesia. These symptoms and their response to levodopa constitute the basis for a clinical diagnosis of Parkinson's disease. Postural instability and gait abnormalities occur in more advanced disease. Although there is no cure for Parkinson's disease, a number of pharmacologic treatments are available for managing the motor and nonmotor symptoms. Research is under way to assess the disease-modifying ability of both standard and newer treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18041935     DOI: 10.1592/phco.27.12part2.155S

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  24 in total

1.  Zonisamide in Parkinson's disease: profile report.

Authors:  Lily P H Yang; Caroline M Perry
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

2.  Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.

Authors:  Przemysław Nowak; Rose Anna Kostrzewa; Dariusz Skaba; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2009-09-04       Impact factor: 3.911

3.  Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models.

Authors:  Mrittika Chattopadhyay; Anindya Roy Chowdhury; Ting Feng; Charles-Antoine Assenmacher; Enrico Radaelli; F Peter Guengerich; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2019-05-20       Impact factor: 5.157

4.  The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2.

Authors:  Michela Campolo; Giovanna Casili; Flavia Biundo; Rosalia Crupi; Marika Cordaro; Salvatore Cuzzocrea; Emanuela Esposito
Journal:  Antioxid Redox Signal       Date:  2017-01-27       Impact factor: 8.401

5.  Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.

Authors:  Ghada A Badawi; Mai A Abd El Fattah; Hala F Zaki; Moushira I El Sayed
Journal:  Inflammopharmacology       Date:  2017-03-04       Impact factor: 4.473

6.  Diffusion tensor imaging parameters' changes of cerebellar hemispheres in Parkinson's disease.

Authors:  Enricomaria Mormina; Alessandro Arrigo; Alessandro Calamuneri; Francesca Granata; Angelo Quartarone; Maria F Ghilardi; Matilde Inglese; Alessandro Di Rocco; Demetrio Milardi; Giuseppe P Anastasi; Michele Gaeta
Journal:  Neuroradiology       Date:  2014-12-06       Impact factor: 2.804

7.  Zonisamide: in Parkinson's disease.

Authors:  Lily P H Yang; Caroline M Perry
Journal:  CNS Drugs       Date:  2009-08       Impact factor: 5.749

8.  Zonisamide attenuates MPP+-induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells.

Authors:  Vedat Ali Yürekli; Semih Gürler; Mustafa Nazıroğlu; Abdülhadi Cihangir Uğuz; Hasan Rifat Koyuncuoğlu
Journal:  Cell Mol Neurobiol       Date:  2012-11-15       Impact factor: 5.046

Review 9.  Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.

Authors:  Jacobus P Petzer; Neal Castagnoli; Michael A Schwarzschild; Jiang-Fan Chen; Cornelis J Van der Schyf
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

10.  miR-101-3p Contributes to α-Synuclein Aggregation in Neural Cells through the miR-101-3p/SKP1/PLK2 Pathway.

Authors:  Min Zhang; Wei Liu; Qingan Zhang; Hongfeng Hu
Journal:  J Healthc Eng       Date:  2021-06-12       Impact factor: 2.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.